Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.30 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.30 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.30 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.30 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.30 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.30 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.30 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.30 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355536 | 0.82 | SOS1 (0.33) | — | |
| SCHEMBL17355419 | 0.81 | — | — | |
| SCHEMBL13808391 | 0.79 | GAA (0.36) | GAA | |
| SCHEMBL17355508 | 0.78 | — | — | |
| SCHEMBL17355477 | 0.77 | EPHX2 (0.38) | — | |
| SCHEMBL13808393 | 0.76 | CYP1A2 (0.34) | GAA | |
| SCHEMBL17355424 | 0.75 | ALOX5AP (0.37) | — | |
| SCHEMBL13808401 | 0.73 | L3MBTL1 (0.39) | — | |
| SCHEMBL1568066 | 0.71 | PDE2A (0.38) | — | |
| SCHEMBL30730980 | 0.71 | PDE2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1828345-B1 | BIMESOGENIC COMPOUNDS AND FLEXOELECTRIC DEVICES | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MLX, FOXM1, SFXN1 | GAA 4632/4885EGFR 2013/4885TUBB4A 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.